Biotest AG, Friday announced that its parent company Grifols, S.A. (GRFS) has received approval from the U.S. Food and Drug Administration for Fesilty, a human fibrinogen product developed for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency.
With this approval, Grifols will be able to launch this product in the first half of 2026 in the U.S.
Dr. Jörg Schüttrumpf, Chief Executive Officer of Biotest AG, said, "We are proud that our plasma expertise contributes directly to expanding patient access to life-saving fibrinogen therapies in the treatment of critical conditions worldwide."
Currently, GRFS is trading at $8.99, up 0.84 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.